WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the third quarter ended September 30, 2016. Detailed in this press release are the Company’s performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today’s webcast and conference call.
Tony J. Hunt, President and Chief Executive Officer said, “During the third quarter of 2016, product sales grew to $24.7 million, an increase of 25% from the same period in 2015. Our continued growth during the quarter was driven by strong demand for our direct portfolio of products, in particular our XCell™ ATF systems and OPUS® columns. It was also an important period with respect to advancing new products, with the launch of a single-use version of our XCell™ ATF system, and the introduction of a new resin recovery feature on our large OPUS® columns. Our continued investments in new product development, capacity expansion and people to support our expanding franchises position us well for a strong finish to 2016 and into 2017.”
